You are currently viewing a new version of our website. To view the old version click .

Biologics, Volume 3, Issue 2

June 2023 - 4 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (4)

  • Review
  • Open Access
6 Citations
4,218 Views
20 Pages

A Review on the Impact of the SARS-CoV-2 Omicron Subvariant on Elderly Patients with Diverse Co-Morbidities

  • Avinash Khadela,
  • Shruti Soni,
  • Kaivalya Megha,
  • Shivam Bhagat and
  • Vivek P. Chavda

9 June 2023

The SARS-CoV-2 virus has caused a catastrophic impact on the world for the past 3 years. The virus has now returned with the emergence of the Omicron (B.1.1.529) variant. Within two months of its first emergence in South Africa, Omicron became the mo...

  • Review
  • Open Access
3 Citations
4,303 Views
22 Pages

Aptamers as Insights for Targeting SARS-CoV-2

  • Suna Karadeniz Saygılı,
  • Anna Szymanowska,
  • Gabriel Lopez-Berestein,
  • Cristian Rodriguez-Aguayo and
  • Paola Amero

11 May 2023

The Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) continues to be a major cause of high mortality in the world. Despite many therapeutic approaches having been successfully developed, there is still the need to find novel and more effect...

  • Systematic Review
  • Open Access
2 Citations
4,584 Views
21 Pages

Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies

  • Maria Maddalena Nicoletti,
  • Erminia Crisci,
  • Ciro Pentella,
  • Andrea Cantone,
  • Donatella Ruggiero,
  • Antonietta Anatriello and
  • Cristina Scavone

27 April 2023

Background. Although biosimilars have been increasingly used over recent years, some concerns about a potential loss of efficacy and altered safety profile when switching from an originator to a biosimilar still exist. Interchangeability can be a cha...

  • Review
  • Open Access
5 Citations
7,265 Views
23 Pages

19 April 2023

Reinventing approved therapeutic proteins for a new dose, a new formulation, a new route of administration, an improved safety profile, a new indication, or a new conjugate with a drug or a radioactive source is a creative approach to benefit from th...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Biologics - ISSN 2673-8449